Newer approaches to therapy of hepatic encephalopathy

Seminars in Liver Disease

Volumn 16, Issue 3, 1996, Pages 329-338

  Ferenci, Peter ^a   Herneth, Andreas ^a   Steindl, Petra ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 OXOGLUTARIC ACID; AMMONIA; ANTIBIOTIC AGENT; ASPARTIC ACID; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZOIC ACID; BRANCHED CHAIN AMINO ACID; BROMOCRIPTINE; CARNITINE; DISACCHARIDE; ENEMA; FLUMAZENIL; LACTITOL; LACTULOSE; LEVODOPA; MELATONIN; METERGOLINE; METHYSERGIDE; METITEPINE; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; ORNITHINE; SEROTONIN ANTAGONIST; ZINC;

CLINICAL TRIAL; DIET THERAPY; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERAMMONEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; NITROGEN METABOLISM; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0030480466     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007245     Document Type: Review

References (71)

1. Ferenci P, Püspök A, Steindl P: Current concepts in the pathophysiology of hepatic encephalopathy. Eur J Clin Invest 22:573-81, 1992.
2. Uribe M, Campollo O, Vargas F: Acidifying enemas (lactitol and lactulose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind randomized clinical trial. Hepatology 7:639-4, 1987.
3. Bockel R, Doffoel M, Lavage digestif au mannitol dans les hemorragies digestives du cirrhotique. Nouv Presse Med 1981;10:33-36
4. Conn HO, Leevy CM, Vlahcevic ZR, et al: Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology 72:573-83, 1977.
5. Bucci L, Palmieri GC: Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 13:109-18, 1993.
6. Tarao K, Ikeda T, Hayashi K, et al: Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 31:702-6, 1990.
7. Mortensen PB, Holtug K, Bonnen H, Clausen MR: The degradation of amino acids, proteins, and blood to short-chain fatty acids in colon is prevented by lactulose. Gastroenterology 98:353-60, 1990.
8. Conn HO, Lieberthal MM: The Hepatic Coma Syndromes and Lactulose. Baltimore, Williams & Wilkins, 1979.
9. Van Thiel DH, Fagiuoli S, Wright HI, et al: Gastrointestinal transit in cirrhotic patients: effect of hepatic encephalopathy and its treatment. Hepatology 19:67-71, 1994.
10. Mortensen PB: The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion. Hepatology 16:1350-6, 1992.
11. Bircher J, Müller J, Guggenheim P, et al: Treatment of chronic portal-systemic encephalopathy with leactulose. Lancet i:890-3, 1966.
12. Orlandi F, Brunelli F, Benedetti A, Macarri G: Clinical trials of nonabsorbable disaccharide therapy in hepatic encephalopathy. In: Conn HO, Bircher J. (eds): Hepatic Encephalopathy. Syndromes and Therapies. Bloomington, Medi-Ed Press, 1994, pp 209-18.
13. Morgan MY, Hawley KE: Lactitol vs lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind, randomized trial. Hepatology 7:1278-84, 1987.
14. Salerno F, Moser P, Maggi A, et al: Effects of long-term administration of low-dose lactitol in patients with cirrhosis but without overt encephalopathy. J Hepatol 21:1092-6, 1994.
15. Uribe M, Marquez MA, Gargaramos G, et al: Treatment of chronic portal systemic encephalopathy with lactose in lactase deficient patients. Dig Dis Sci 25:914-28, 1980.
16. Loguercio C, Abbiati R, Rinaldi M, et al: Long-term effects of enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 23:39-46, 1995.
17. Häussinger D: Nitrogen metabolism in liver: structural and functional organization and physiologic relevance. Biochem J 267:281-90, 1990.
18. Kircheis G, Quack G, Erbler H: L-ornithine-L-aspartate in the treatment of hyperammonemia and hepatic encephalopathy. In: Conn HO, Bircher J. (eds): Hepatic Encephalopathy. Syndromes and Therapies. Bloomington, Medi-Ed Press, 1994, pp 373-83.
19. Staedt U, Leweling H, Gladisch R, et al: Effects of omithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a fourfold crossover design. J Hepatol 19:424-30, 1993.
20. Mendenhall CL, Rouster S, Marshall L, Weesner R: A new ther-apy for portal systemic encephalopathy. Amer J Gastroenterol 81:540-3, 1986.
21. Sushma S, Dasarathy S, Tandon RK, et al: Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 16:138-44, 1992.
22. O'Connor JE, Costell M, Grisolia S: Protective effect of L-carnitine on hyperammonemia. FEBS Lett 30:331-4, 1984.
23. Hearn TJ, Coleman AE, Lai JCK, et al: Effect of orally administered L-carnitine on blood ammonia and L-carnitine concentrations in portacaval-shunted rats. Hepatology 10:822-8, 1989.
24. Del Olmo JA, Castillo M, Rodrigo JM, et al: Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients. In: S. Grisolia et al, (eds): Cirrhosis Hepatic Encephalopathy, and Ammonium Toxicity. Plenum Press, New York, 1990, pp 197-208.
25. Stumpf DA, Parker WD, Angelini C: Carnitine deficiency, organic acidemias and Reye's syndrome. Neurology 35:1041-5, 1985.
26. Rudman D, Sewell CW, Ansley JD: Deficiency of carnitine in cachectic cirrhotic patients. J Clin Invest 60:716-23, 1977.
27. Fischer JE, Funovics J, Aguirre A: The role of plasma amino acid in hepatic encephalopathy. Surgery 78:276-90, 1975.
28. Ferenci P: Critical evaluation of the role of branched chain amino acids in liver disease. In: Thomas JC, Jones EA (eds): Recent Advances in Hepatology New York, Churchill Livingstone, 1986, pp 137-54.
29. Naylor CD, O'Rourkee K, Detsky AS, Baker JP: Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 97:1033-42, 1989.
30. Egberts EH, Schomerus H, Hamster W, Jürgens P: Branched chain amino acids in the treatment of latent portosystemic encephalopathy. Gastroenterology 88:887-95, 1985.
31. Marchesini G, Dioguardi FS, Bianchi GP, et al: Longterm branched chain amino acid treatment in chronic hepatic encephalopathy. J Hepatol 11:92-101, 1991.
32. Horst D, Grace ND, Conn HO, et al: Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 4:279-87, 1984.
33. Grimm G, Ferenci P, Katzenschlager R, et al: Improvement of hepatic encephalopathy treated with flumazenil. Lancet ii: 1392-4, 1988.
34. Bansky G, Meier PE, Riederer E, et al: Effects of the benzodiazepine receptor antagonist flumazenil in hepatic encephalopathy in humans. Gastroenterology 97:744-53, 1989.
35. Ferenci P, Grimm G, Meryn S, Gangl A: Successful long-term treatment of portal systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology 96:240-3, 1989.
36. Pomier-Layrargues JF, Giguère J, Lavoie J, et al: Pharmakokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction. Hepatology 10:969-72, 1989.
37. Basile AS, Harrison PM, Hughes RD, et al: Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 19:112-21, 1994.
38. Pomier-Layrargues JF, Giguère J, Lavoie J, et al: Flumazenil in cirrhotic patients in hepatic coma: A randomized double-blind placebo-controlled crossover trial. Hepatology 19:32-7, 1994.
39. Cadranel JF, el Younsi M, Pidoux B, et al: Flumazenil therapy for hepatic encephalopathy in cirrhotic patients: a double-blind pragmatic randomized, placebo study. Eur J Gastroenterol Hepatol 7:325-9, 1995.
40. Van der Rijt CC, Schalm SW, Meulstee J, Stijnen T: Flumazenil therapy for hepatic encephalopathy. A double-blind cross over study. Gastroenterol Clin Biol 19:572-80, 1995.
41. Gyr K, et al: Synopsis of research report B-154′321 (Protocol N-12725a), Hoffmann-La Roche, 1993.
42. Jones EA, Gammal SA: Hepatic encephalopathy. In: Arias I, Jakoby WB, Popper H. (eds): The Liver: Biology and Pathobiology. New York, Raven Press, 1988.
43. Amodio P, Marchetti P, Comacchio F, et al: Effects of flumazenil on subclinical hepatic encephalopathy: preliminary data. Ital J Gastroenterol 25:183, 1993.
44. Michel H, Solere M, Grainer P: Treatment of cirrhotic hepatic encephalopathy with L-Dopa: a controlled trial. Gastroenterology 79:207-11, 1980.
45. Morgan M Jakobovits AW, James M, Sherlock S: Successful use of bromocriptine in the treatment of hepatic encephalopathy. Gastroenterology 78:663-70, 1980.
46. Uribe M, Farca A, Marquez MA, et al: Treatment of chronic portal systemic encephalopathy with bromocriptine. Gastroenterology 76:1347-51, 1979.
47. Jellinger K, Riederer P, Kleinberger G, et al: Brain monoamines in human hepatic encephalopathy. Acta Neuropathol (Berl) 43:63-8, 1978.
48. Yurdaydin C, Hörtnagl H, Steindl P, et al: Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide induced acute liver failure. Hepatology 12:695-700, 1990.
49. Rao VL, Butterworth RF: Alterations of [3H]8-OH-DPAT and [3H]ketanserin binding sites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurosci Lett 182:69-72, 1994.
50. B in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Brain Res 621:349-52, 1993.
51. Bugge M, Bengtsson F, Nobin A, et al: The turnover of brain monoamines after total hepatectomy in rats infused with branched chain amino acids. World J Surg 11:810-17, 1987.
52. Mousseau-DD, Butterworth-RF: The [3H]tryptamine receptor in human brain: kinetics, distribution, and pharmacologic profile. J Neurochem 63:1052-9, 1994.
53. Zifa E, Fillion G: 5-hydroxytryptamine receptors. Pharmacolog Rev 44:401-58, 1992.
54. Peroutka SJ: 5-hydroxytryptamine receptors. J Neurochem 60:408-16, 1993.
55. 1A agonistic properties. Hepatology 20:108A, 1994.
56. Krulich L, McCann SM, Mayfield MA: On the mode of the prolactin release-inhibiting action of the serotonin blockers metergoline, methysergide and cyproheptadine. Endocrinology 108:1115-24, 1981.
57. Yurdaydin C, Li Y, Ha JH, et al: Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists. J Pharmacol Exp Ther 273:185-92, 1995.
58. Lisker-Melman M, Moreno-Otero R, Fromm HC, et al: Behavioural amelioration of hepatic encephalopathy by an opiate receptor antagonist in a rat model. Hepatology 8:1247, 1988.
59. Steindl PE, Finn B, Bendok B, et al: Disruption of the diurnal rhythm of plasma melatonin in cirrhosis. Ann Int Med 123:274-7, 1995.
60. Rosenthal NE: Plasma melatonin as a measure of the human clock. J Clin Endocrinol Metab 225-6, 1991.
61. Lewy AJ, Ahmed S, Latham Jackson JM, Sack RL: Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int 9:380-92, 1992.
62. Halsted JA, Hackley B, Rudzsi C, Smith JC: Plasma zinc concentration in liver diseases. Comparison with normal controls and certain other chronic diseases. Gastroenterology 54:1098-1105, 1968.
63. Zeneroli ML, Baraldi M: Neurotransmission in hepatic encephalopathy. Adv Exp Med Biol 272:135-48, 1990.
64. Van der Rijt CC, Schalm SW, Schat H, et al: Overt hepatic encephalopathy precipitated by zinc deficiency. Gastroenterology 100:1114-8, 1991.
65. Reding P, Duchateau J, Bataille C: Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial. Lancet ii:493-5, 1984.
66. Bresci G, Parisi G, Banti S: Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment. EUR J Med 2:414-6, 1993.
67. Riggio O, Ariosto F, Merli M, et al: Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci 36:1204-8, 1991.
68. Uribe M, Marquez MA, Ramos GG, et al: Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets. Dig Dis Sci 27:1109-16, 1982.
69. Bianchi GP, Marchesini G, Fabbri A, et al: Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. J Intern Med 233:385-92, 1993.
70. Greenberger NJ, Carley J, Schenker S, et al: Effect of vegetable and animal protein diets in chronic hepatic encephalopathy. Dig Dis Sci 22:845-55, 1977.
71. Weber FL, Minco, D, Fresard KM, Banwell JG. Effects of vegatable diets on nitrogen metabolism in cirrhotic subjects. Gastroenterology 89:538-44, 1985.